Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENGRUI PHARMA's Anti-tumor Drug HRS-6093 Receives Approval from CN for Clinical Trials
Recommend 12 Positive 13 Negative 6 |
||||
|
||||
|
HENGRUI PHARMA (01276.HK) announced that its anti-tumor drug HRS-6093 had received a notification of approval for clinical trials from China's National Medical Products Administration. The clinical trials are set to commence in the near future. Up to now, HENGRUI PHARMA said it had poured around RMB29.84 million into the R&D of the projects related to the HRS-6093. The HRS-6093 is a new, highly effective, and selective oral KRAS G12D inhibitor. No similar products have been approved for marketing in China and overseas. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
